

September 14-16, 2020 | Digital Event

8:30am - 5:30pm EDT | 5:30am - 2:30pm PDT

www.ras-drugdevelopment.com

BOOK NOW TO
JOIN THE
DISCUSSION!

2nd Annual

RAS-Targeted Drug Development

Finally Bring an End to RAS Driven Cancer

Explore Novel Discoveries, Identify Rational
Anti-RAS Combination Strategies & Accelerate
the Translation of Next Generation RAS-Mutant
Targeted Therapies into Human Clinical Trials

Expert Speakers Include:



Frank McCormick
Professor & Leader
NCI RAS Initiative
**Frederick National
Laboratory for
Cancer Research**



Channing Der
Sarah Graham
Kenan Distinguished
Professor
**University of North
Carolina at Chapel
Hill**



Steve Kelsey
President R&D
**Revolution
Medicines**



Peter Hammerman
Global Head of
Translational
Oncology
Novartis



Shiva Malek
Senior Director &
Head of Discovery
Oncology
Genentech



Lusong Luo
Senior Vice President,
External Innovation
BeiGene

Proud to Partner with:



Welcome to the Digital 2nd RAS-Targeted Drug Development Summit

Explore Novel Discoveries, Identify Rational Anti-RAS Combination Strategies & Accelerate the Translation of Next Generation RAS-Mutant Targeted Therapies into Human Clinical Trials

Following the exciting summit in September 2019, we are delighted to be reuniting the RAS community with the flagship **2nd RAS-Targeted Drug Development Summit**. This comprehensive and definitive digital platform will bring together the largest community of RAS experts from large pharma, innovative biotech and research institutes, focused on capitalizing the emerging therapeutic and commercial opportunity to finally bring an end to RAS driven cancers.

Despite continual efforts to successfully develop RAS targeted therapies, there remain no such treatments on the market. Thus, RAS drug discovery and developmental success will reap significant patient benefits and tremendous commercial outcomes. As the first KRAS inhibitors to reach the clinic show promising opportunity to address unmet clinical need, it is essential to drive forward the clinical translation of first generation of anti-RAS therapies but also stimulate discussion into **next generation RAS-mutant targeted therapies** that harness different modalities and pathways to target RAS driven cancers **beyond the KRAS G12C mutation**.

Utilizing latest data-driven case studies from academic and industry pioneers, join the RAS community for discussions focused on **optimizing the selectivity and tolerability** of your anti-RAS therapies, **exploring novel combination strategies** and **overcoming translational pharmacology challenges** to set the stage for the second generation of mutation-targeted RAS modulating therapies yet to come.

Same High Quality Program, Delivered To You Digitally



42+

World-Class Speakers



32+

Late-Breaking Case Studies



2

Dedicated Streams



6

Technical Workshops



250+

Senior Attendees




8+

Hours of Dedicated Networking


What to Expect at the 2nd RAS-Targeted Drug Development Summit



Explore how to leverage the internal structural biology of RAS mutations in order to produce effective and clinically viable therapies with discussions from **D.E Shaw Research, The Johns Hopkins University School of Medicine & Hospital for Sick Children**




Deep dive into RAS associated pathways in order to optimize combination therapies with insights from **Novartis, Genentech & Deciphera Pharmaceuticals**



Evaluate the mechanisms of action and resistance of RAS targets to accelerate target validation and clinical translation with insights from **Abbvie, PhoreMost & Verastem Oncology**



Adopt novel techniques to successfully target therapeutic vulnerabilities in RAS-driven cancers with lessons learnt from **BeiGene, Aelin Therapeutics, Oblique Therapeutics & Aro Biotherapeutics**



Explore the successes and future therapeutic potential of targeting mutations beyond G12C from within the RAS community explored **Revolution Medicines, Francis Crick Institute & MD Anderson Cancer Centre**

YOUR EXPERT SPEAKERS

PIONEERING ACADEMICS



Frank McCormick
Professor & Leader NCI
RAS Initiative
**Frederick National
Laboratory for Cancer
Research**



Channing Der
Sarah Graham Kenan
Distinguished Professor
**University of North
Carolina at Chapel Hill**



Piro Lito
Assistant Member
**Memorial Sloan
Kettering Center**



Ryan Corcoran
Associate Professor of
Medicine
**Harvard Medical
School**




Aaron Hata
Assistant Professor of
Medicine
**Harvard Medical
School**



Scott Kopetz
Distinguished Professor
**MD Anderson Cancer
Centre**



Martin McMahon
Presidential Chair of
Cancer Biology
**Huntsman Cancer
Institute of University
of Utah**



Greg Beilhartz
Senior Research
Associate
**The Hospital for Sick
Children**



Christine Pratilias
Associate Professor of
Oncology & Pediatrics
**Sidney Kimmel
Comprehensive Cancer
Center at Johns Hopkins**



Miriam Molina-Arcas
Senior Laboratory
Research Scientist
Francis Crick Institute



Jack Arbiser
Thomas Lawley
Professor of
Dermatology
**Emory University
School of Medicine**



Antti Poso
Professor of Drug
Design
**University of Eastern
Finland & University
Hospital Tübingen**



Pan-Yu Chen
Postdoctoral Fellow
**University of
California**



Behnam Nabet
Katherine Loker Pinard
Fellow
**Dana-Farber Cancer
Institute**



Bruce Gelb
Gogel Family Chair &
Director
**Mindich Child Health
& Development
Institute**



Udai Banerji
Professor & Deputy
Director of The Drug
Development Unit
**The Institute of
Cancer Research,
London**

GLOBAL LEADERS FROM LARGE PHARMA & BIOTECH



Steve Kelsey
President R&D
Revolution Medicines



Peter Hammerman
Global Head of
Translational Oncology
Novartis



Alexander Scheer
Chief Scientific Officer
Aelin Therapeutics



Bryan Smith
 Vice President of
 Biological Sciences
**Deciphera
 Pharmaceuticals**



Francis Burrows
 Vice President of
 Translational Research
Kura Oncology



Jonathan Pachter
 Chief Scientific Officer
Verastem Oncology



Erik Digman-Wiklund
 Chief Business Officer
Targovax



Lusong Luo
 Senior Vice President,
 External Innovation
Beigene



Steven Fruchman
 President & Chief
 Executive Officer
**Onconova
 Therapeutics**



Mark Erlander
 Chief Executive Officer
Cardiff Oncology



Silvia Coma
 Associate Director
 Preclinical Research
Verastem Oncology



Jan Smith
 Vice President Biology
Revolution Medicines



Sreesha Srinivasa
 Senior Vice President
Oblique Therapeutics



Steven Nadler
 Vice President of
 Research
Aro Biotherapeutics



Matt Meyer
 Senior Director & Head
 of In Vivo Biology
Bristol Myers Squibb



Tauseef Butt
 Chief Executive Officer
Progenra



Shiva Malek
 Senior Director & Head
 of Discovery Oncology
Genentech



Pete DeMuth
 Vice President of
 Research
Elicio Therapeutics



Grahame McKenzie
 Chief Scientific Officer
PhoreMost



Beth Stronach
 Board Member &
 Parent Advocate
RASopathies Network



Erica Jackson
 Senior Director
AbbVie



Marie Evangelista
 Senior Scientist &
 Project Team Lead,
 Discovery Oncology
Genentech



Yibing Shan
 Senior Scientist
D.E Shaw Research



Nicholas Heimann
 Chief Executive Officer
**Nicholas
 Pharmaceuticals LLC**



Chiara Ambrogio
 Assistant Professor
University of Turin



Ida Aronchik
 Principal Scientist
Bristol Myers Squibb

INNOVATING SOLUTION PROVIDERS



Matt Robers
 Senior Research
 Scientist, Integrated
 Biology, R&D
Promega



Kerstin Pohl
 Manager of Medical
 Affairs
Biodesix

WHY ARE OUR EXPERT SPEAKERS GETTING INVOLVED IN THE SUMMIT?

“ This meeting brings together experts in RAS biochemistry, genetics, cell biology & pharmaceuticals with the goal of coming up with new ways to target therapeutic vulnerabilities in RAS-driven cancers. As such, the meeting is timely, interesting and important to everyone who works in the field of RAS ”



Martin McMahon
Presidential Chair of
Cancer Biology
**Huntsman Cancer
Institute of
University of Utah**

“ I look forward to networking with other researchers, hearing the most recent ideas and directions for targeting RAS & establishing new connections ”



Channing Der
Sarah Graham Kenan
Distinguished Professor
**University of North
Carolina at Chapel
Hill**

“ Targeting RAS remains a significant technical challenge, but numerous efforts are underway and are likely to have major clinical benefits in the future and therefore warrant close attention ”



Frank McCormick
Professor & Leader NCI
RAS Initiative
**Frederick National
Laboratory for Cancer
Research**

“ Combination approaches to RAS mutant cancers may be needed. I'm excited to see new developments in targeting RAS as well as combination approaches that may deliver new therapies for these cancers ”



Bryan Smith
Vice President of
Biological Sciences
**Deciphera
Pharmaceuticals**

“ There has been a huge increase in the number of RAS-directed therapies. I look forward to industry-based experts to come together with academia and discuss progress, challenges and collaborations ”



Steve Kelsey
President R&D
Revolution Medicines

Digital Events: An Interactive Online Experience

The **2nd RAS-Targeted Drug Development Summit** is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created the virtual summit to satisfy the industry’s need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you’ll be provided with a unique link in the run up to the event that will take you directly to the online event space where you’ll follow a few simple steps to set up your delegate profile and get started.





Key Features Of The Virtual Summit

Our mission remains dedicated to ensuring the RAS community have the tools & the means to streamline for patients in need. Although we may not meet in person, we uphold our promise to unite the RAS community.

Whilst face-face meetings are put on hold, we continue to deliver the key features of a physical meeting in an optimal digital world:

 <p>Delegate Profile Set up personalized profiles to easily identify the name, job title & company of other attendees</p>	 <p>Stage Area Most presentations will be delivered in the ‘Stage’ area, much like the main conference room onsite</p>	 <p>Sessions Area Smaller groups can get together in this breakout area for panel discussions and other interactive sessions</p>
 <p>Demo Area Visit the virtual exhibition area to explore the solutions our specialist vendors have on offer</p>	 <p>Chat Rooms Connect with your peers and start conversations with individuals or all attendees in private and public chatrooms</p>	 <p>Speed Networking This virtual networking session will connect you with other attendees to establish new industry contacts</p>

What You Can Expect from a Digital Event:

 <p>Live Q&A Ask your questions directly to presenters in real-time, just as you would face-to-face. Make your voice heard and jump on the screen to share your thought</p>	 <p>Audience Discussions Interactive speed networking will allow you to meet and network with your peers. In addition, join our informal “meeting rooms” where up to 10 guests can join an interactive and informal chat</p>	 <p>Virtual Exhibition Hall Take a tour around our virtual exhibition hall. Leading vendors will be waiting to show you how they can aid your RAS targeted drug into clinic. Easily exchange business cards to keep the conversation going!</p>	 <p>Private Message Attendees Grab an old colleague or a new connection and invite them to a personal meeting room. Using our bespoke chat function, you can see all attendees in real-time and invite them for a conversation</p>
--	---	---	---

If you have any other questions about the platform, please visit our [FAQ page](#)

PRE-CONFERENCE WORKSHOP DAY MONDAY, SEPTEMBER 14

8:30AM - 4:30PM EDT | 5:30AM - 1:30PM PDT

 **8.30 | 5.30 Online Registration & Virtual Coffee Networking**

Workshop A

9.00 | 6.00 Expanding Novel Approaches Towards RAS Drug Discovery with Degradation Strategies

Ubiquitylation and degradation of RAS is one of the key mechanisms for covalent and PROTAC RAS drugs. As ubiquitylation masks target protein epitope, monitoring degradation ubiquitylation and degradation of RAS need to be explored with new methods. Navigating through clinical and preclinical, it is important to consider the use of covalent and non-covalent RAS inhibitors and their mechanisms. Similarly, evaluating the value of biochemical, cellular and imaging methods will aid effective drug discovery.

Topics to be covered:

- Discuss and highlight why RAS proteins are so undruggable
- Explore the possibility of drugging different RAS isoforms with a universal inhibitor?
- Describe the structure and ubiquitous nature of GTP binding properties that makes it difficult to target
- Consider how ubiquitylation and de-ubiquitylation plays a big role in stability of RAS
- Discover the most efficient methods to monitor ubiquitylation of RAS proteins



Tauseef Butt
Chief Executive Officer
Progenra

Workshop B

9.00 | 6.00 Exploring Allosteric Modulation of RAS: Utilizing Recent Data to Rethink RAS Experimentation

Our understanding how RAS proteins interact with GTP and downstream kinases has become more solid thanks to new structural biology and theoretical chemistry data. At the same time, basic assumptions about RAS/GTP and RAS/kinase binding dynamics are under re-evaluation. In the workshop we will look to discuss these fundamentals and how those effect on drug design and even clinical experiment. Through this updated detailed understanding of the structural modulation it is possible we can advance RAS-targeted therapies.

Topics to be covered:

- RAS-GTP and RAS-kinase recognition mechanisms
- Based on recent findings, should we rethink conduction of experiments and interpretation of RAS data?



Antti Poso
Professor of Drug Design
**University of Eastern Finland & University
Hospital Tübingen**

 **11.00 | 8.00 Morning Break & Virtual Speed Networking**

Workshop C

11.30 | 8.30 Navigating the Future Potential of Combination Strategies: Combining Inhibitors Inside & Outside the RAS Pathway

As combination strategies become more abundant in our labs and increasingly important to targeted RAS, still our knowledge is limited. It is important to discuss how to best use combination strategies to optimize therapies for patients with RAS-driven cancers. This workshop will facilitate discussion around both combining inhibitors within the RAS pathway and targets outside the RAS pathway and how to select optimal combinations of RAS pathway inhibitor. It will also cover the potential of biomarkers to select of the right combination to overcome RAS inhibitor failure.

Topics to be covered:

- What combination strategies make sense within the RAS pathway, and why?
- What combinations may be required outside the canonical RAS-signalling pathway?
- How can we select patients or combinations for RAS-driven cancers up front?
- How can we select or predict the best combination at progression or failure of RAS inhibitors?



Jan Smith
Vice President Biology
Revolution Medicines



Ryan Corcoran
Associate Professor of Medicine
Harvard Medical School

Workshop D

11.30 | 8.30 Mechanisms of Resistance: Identifying Effective Tools & Techniques to Accelerate Anti-RAS Drug Development

Approximately 30% of all cancers present with mutations in one of the RAS genes, making the RAS family the most prevalent oncogenic driver in human cancer. Targeted therapies against oncogenic drivers have led to dramatic responses clinical responses. Unfortunately, these responses are often short-lived due to the acquisition of drug resistance through a variety of genetic and non-genetic mechanisms. In order to maximize the success of RAS-targeted therapies, it will be important to gain an early understanding of the mechanisms driving resistance to inhibitors with diverse MOA's. With this in mind, it is important to delve into the most effective tools and techniques to study these resistance mechanisms. Understanding such mechanisms may enhance patient selection and combination strategies and accelerate anti-RAS drug discovery and development.

Topics to be covered:

- Review our current understanding of resistance mechanisms to anti-RAS therapies
- Explore available and potential tools to study mechanism of resistance
- Discuss best approaches to resistance modeling



Erica Jackson
Senior Director
AbbVie



Marie Evangelista
Senior Scientist &
Project Team Lead,
Discovery Oncology
Genentech

PRE-CONFERENCE WORKSHOP DAY MONDAY, SEPTEMBER 14

8:30AM - 4:30PM EDT | 5:30AM - 1:30PM PDT

 **1.30 | 10.30 Lunch & Virtual Networking**

Workshop E

2.00 | 11.00 **Enhancing Applicability, Specificity & Effectivity: Leveraging the Potential of a Protein Aggregation Based Platform to Transform RAS Drug Discovery**

Whilst RAS proteins remain promising targets for anti-cancer therapies, the inability to effectively target such proteins remains a salient challenge for the RAS community. With the protein-aggregation based platform, effective and selective targeting of RAS proteins becomes more achievable. Through harnessing this new technology, we can overcome challenges surrounding discovery of RAS-targeted therapies and effectively drug the “undruggable”

Topics to be covered:

- Outline the technology and potential of the protein aggregation platform
- Aelin’s platform as an alternative in the space of PROTAC’s (Proteolysis Targeting Chimeric’s)



Alexander Scheer
 Chief Scientific Officer
Aelin Therapeutics

Workshop F

2.00 | 11.00 **Exploring How RASopathy Syndromic Disorders Will Help Target the RAS Pathway**

This workshop will introduce the ‘RASopathies’, a group of neurodevelopmental genetic syndromes caused by germline mutations in genes encoding members of the RAS-MAPK signaling pathway. Amongst the 20 different genes implicated in RASopathy syndromes most mutations result in activation of RAS signaling. Discussions will consider how knowledge of RAS mutant cancers and cancer therapeutics can inform treatment of RASopathies, as well as how cancer biology may benefit from understanding the role of RAS signaling in human development revealed by study of the RASopathies.

Topics to be covered:

- What are the RASopathy syndromes, how do they manifest, and how prevalent are they?
- How do RASopathy mutations compare with RAS cancer mutations?
- What can RASopathy variants teach us about RAS signalling biology, mechanisms of action and new target opportunities?
- What preclinical models of RASopathies exist; and what have early/small clinical trials told us?
- What clinical endpoints are amenable to measuring in individuals with RASopathies?



Beth Stronach
 Board Member &
 Parent Advocate
**RASopathies
 Network**



Bruce Gelb
 Gogel Family Chair
 & Director
**Mindich Child
 Health &
 Development
 Institute**

“An informative, non-repetitive meeting allowing interaction for participants. It was great to see all the current approaches that are being used to target RAS by pharmaceutical industries!”

Past Attendee, University of Michigan

CONFERENCE DAY ONE TUESDAY, SEPTEMBER 15

8:30AM - 5:30PM EDT | 5:30AM - 2:30PM PDT

8.50
5.50 **Chair's Opening Remarks**

Frank McCormick **9.00**
 Professor & Leader
 NCI RAS Initiative
**Frederick National
 Laboratory for
 Cancer Research** **6.00** **Exploring the Continual Progression & Efforts to Target RAS**

- Discuss the clinical value for KRAS mutant cancers through targeting the specific isoform G12C
- Highlight the importance of targeting other alleles such as G12D
- Emphasise the feedback responses gained from Inhibiting RAS and the targeting potential for future therapies

Channing Der **9.20**
 Sarah Graham
 Kenan Distinguished
 Professor
**University of North
 Carolina at Chapel
 Hill** **6.20** **Highlighting the Successes of Targeting KRAS in Pancreatic Cancer**

- Exploring why the ERK MAPK cascade is the key effector driving KRAS-dependent pancreatic cancer growth
- Understanding how the MYC oncoprotein and transcription factor is a key ERK target for ERK-dependent pancreatic cancer growth
- Driving altered metabolic processes that support pancreatic cancer growth via the MYC Oncoprotein

Ryan Corcoran **9.40**
 Associate Professor of
 Medicine
**Harvard Medical
 School** **6.40** **Session Details to be Confirmed**

Matt Robers **10.00**
 Senior Research
 Scientist, Integrated
 Biology, R&D
Promega **7.00** **Reaffirming the Functional & Mechanistic Characteristics of KRAS & KRAS Mutants**

- Ensuring intracellular target engagement through KRAS G12C
- Analyzing the interactions between KRAS/BRAF & KRAS/CRAF via live cell kinetic inhibition assays
- Benchmarking HiBIT CRISPR KRAS wildtype and mutant reporter cell lines within clinically relevant backgrounds

10.20
7.20 **Live Panel Q&A**

Ask the speakers your burning questions!



Frank McCormick
 Professor & Leader
 NCI RAS Initiative
**Frederick National
 Laboratory for
 Cancer Research**



Channing Der
 Sarah Graham
 Kenan Distinguished
 Professor
**University of North
 Carolina at Chapel
 Hill**



Ryan Corcoran
 Associate Professor of
 Medicine
**Harvard Medical
 School**



Matt Robers
 Senior Research
 Scientist, Integrated
 Biology, R&D
Promega



11.00
8.00

Virtual Speed Networking & Morning Break

Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!

Early Discovery & Mechanism of Action

Translation & Clinical Development Considerations

Exploring Techniques Beyond Small Molecules Towards Enhanced RAS Targeting

Unlocking Therapeutic Potentials of Targeting RAS Mutations Through Utilizing RAS-Specific Chemistry

12.00 9.00 Generation & Characterization of Antibodies Targeting Mutant KRAS Proteins

- How can we generate selective antibodies for modeling purposes?
- Biochemical characterization is essential for effective KRAS targeting
- Functional characterization in wild type and mutant cancer cell lines



Sreesha Srinivasa
 Senior Vice President
Oblique Therapeutics

12.00 9.00 Exploiting Apoptotic Vulnerabilities of KRAS Mutant Lung Cancer

- Understanding and characterizing diversity of co-occurring mutations in KRAS mutant lung cancers
- How loss of the suppressor LKB1 may alter apoptotic dependencies and confer sensitivity to targeted therapy combinations



Aaron Hata
 Assistant Professor of Medicine
Harvard Medical School

12.20 9.20 Targeting the Lymph Nodes to Enhance Mutant KRAS Specific Vaccine Responses

- Review of Elicio's Lymph Node targeting AMP vaccination platform
- Data showing AMP vaccine-induction of potent mKRAS specific T cell responses
- Review of Elicio's mKRAS clinical development program



Peter DeMuth
 Vice President of Research
Elicio Therapeutics

12.20 9.20 Session Details to be Confirmed



Piro Lito
 Medical Oncologist
Memorial Sloan Kettering Cancer Centre

12.40 9.40 Silencing KRAS with a Centyrin Guided siRNA Conjugate

- Introduction to centyrins and a description of their ability to deliver siRNA into tumor cells
- Discuss effects of centyrin delivered siRNA on knockdown of KRAS mutants in various cells
- Explore the potential therapeutic applications of centyrin siRNA conjugates in KRAS mediated cancer



Steven Nadler
 Vice President of Research
Aro Biotherapeutics

12.40 9.40 Combined Targeting of RAF, MEK & ERK Signalling & Autophagy Treatment of RAS Driven Cancers

- Inhibition of RAF, MEK & ERK signalling in RAS driven cancers cells elicit an increase in autophagy
- Synergistic anti-proliferative effects *in vitro* and promotion of regression of established tumours in preclinical models
- Elevated expression of c-MYC as a marker and a mediator of resistance to combined targeting



Martin McMahon
 Presidential Chair of Cancer Biology
University of Utah

1.00 10.00 Outlining the Structural Model for the RAS-RAF Signalosome

- KRAS signaling is centered on the the large formation of KRAS & RAF assemblies
- How can we harness the RAS-RAF signalosome for experimental structural modeling
- Inhibiting the signalosome formation for the efficacy of drugs targeting KRAS or RAF proteins



Yibing Shan
Senior Scientist
D. E. Shaw Research

1.00 10.00 The Crucial Role of Farnesylation in RAS Mutant Rhabdomyosarcoma

- Outlining common RAS mutations fusion-negative subtype of rhabdomyosarcoma
- Explaining how the farnesyl transferase inhibitor tipifarnib inhibits HRAS membrane localization as opposed to membrane localization of NRAS or KRAS
- Harnessing Tipifarnib as an effective therapeutic strategy for pediatric patients with HRAS mutant solid tumors



Christine Prtilas
Associate Professor of Oncology & Pediatrics
The Johns Hopkins University School of Medicine

1.20 10.20 Live Q&A Panel

- Ask Speakers Your Burning Questions

Panel Chair:



Matt Meyer
Senior Director & Head of In Vivo Biology
Bristol Myers Squibb



**Oblique
Therapeutics**



**Elicio
Therapeutics**



**Aro
Biotherapeutics**



**D. E. Shaw
Research**

1.20 10.20 Live Q&A Panel

- Ask Speakers Your Burning Questions

Panel Chair:



Ida Aronchik
Principal Scientist
Celgene



**Harvard
Medical
School**



**Memorial
Sloan
Kettering
Cancer
Centre**



**University of
Utah**



**The Johns
Hopkins
University
School of
Medicine**



**2.00
11.00 Networking Lunch**

Grab your lunch and join our informal interactive chat rooms to continue the RAS discussions!

Unleashing the Full Potential of Degrading RAS with PROTACs

3.00 12.00 Direct Targeting of RAS by Engineered Chimeric Toxins

- Bacterial enzymes can rapidly and efficiently cleave all RAS isoforms and oncogenic mutants
- Discuss how enzymes can be delivered efficiently into cells expressing specific surface receptors using engineered bacterial toxins
- How will such toxin chimeras show reduction of tumor growth *in vivo*?



Greg Beilhartz
Senior Research Associate,
Hospital for Sick Children

3.20 12.20 PROTAC Mediated Degradation of KRAS

- How ligands bind novel ligases aiding their PROTAC to degrade previously undruggable targets
- Ubiquitylation patterns and types of poly-ubiquitin chains responsible for degradation
- How the application of E3 ligases to degrades undruggable targets and provides an opportunity for breakthrough therapies



Tauseef Butt
Chief Executive Officer
Progenra

Maximizing Translational & Predictive Efforts - Selective Targeting During Combination Therapies

3.00 12.00 Preclinical Studies of ULK Kinase Inhibitor Designed to Inhibit Autophagy

- RAS mutant cancers have high levels of autophagy
- Inhibitors of the MAPK pathway lead to increased autophagy in RAS mutant cancers in preclinical studies to allow for cell survival
- Combination of inhibitors of the MAPK pathway and an inhibitor of autophagy allows for greater efficacy *in vitro* and *in vivo*



Bryan Smith
Vice President of Biological Sciences
Deciphera Pharmaceuticals

3.20 12.20 Single Agent & Combination Activity of Tipifarnib in HRAS Dependent HNSCC


- Discuss the potent and selective farnesyltransferase activity of Tipifarnib
- Explore preclinical models of HRAS-mutant cancer and pivotal testing in HRAS mutant HNSCC patients
- Benchmarking the translational efforts, focused on exploring tipifarnib-anchored combination



Francis Burrows
Vice President of Translational Research
Kura Oncology

3.40 12.40 Identification & Targeting of KRAS-Driven Vulnerabilities Using Degradation Strategies

- Applications of targeted protein degradation
- Case studies highlighting functional evaluation of cancer dependencies including KRAS using the dTAG system
- Development of strategies targeting dependencies in KRAS-driven cancers

 **Behnam Nabet**
 Katherine Loker Pinard Fellow
Dana-Farber Cancer Institute

3.40 12.40 Adopting a Polyvalent Approach to Aid Development of Vaccines Against Mutant RAS

- Update on phase I/II clinical response data in pancreatic cancer
- Use of mutant RAS cfDNA tracking as a predictive tool
- Next steps in combination treatment and new mutant RAS vaccination strategies

 **Erik Digman Wicklund**
 Chief Executive Officer
Targovax


4.00 1.00 Foundation Medicine

- Session Details TBC

4.10 1.10 Live Q&A Panel

- Ask Speakers Your Burning Questions

Panel Chair:

 **Matt Meyer**
 Senior Director & Head of In Vivo Biology
Bristol Myers Squibb

 **Hospital for Sick Children**


 **Progenra**

 **Dana-Farber Cancer Institute**


4.00 1.00 Live Q&A Panel

- Ask Speakers Your Burning Questions

Panel Chair:

 **Ida Aronchik**
 Principal Scientist
Celgene

 **Deciphera Pharmaceuticals**

 **Kura Oncology**

 **Targovax**

4.40

1.40 Chair's Closing Remarks & End of Digital Conference Day One

▀▀ An enriching experience & a great opportunity to hear from the leaders in the RAS research & development field ▀▀
Past Attendee, SpringWorks Therapeutics

CONFERENCE DAY TWO WEDNESDAY, SEPTEMBER 16

8:30AM - 5:30PM EDT | 5:30AM - 2:30PM PDT

8.30

5.30 Opening Remarks & Virtual Coffee Networking

Steve Kelsey
 President R&D
**Revolution
 Medicines**

9.00

6.00 Approaches to Inhibiting RAS Driven Tumors Beyond KRAS G12C

- Targeting the ON form of KRAS G12C
- Targeting mutant form of RAS beyond G12C
- Relevant combinations to achieve synergy in KRAS mutant cancers

9.20

6.20 Exploration of Synergistic Effects: RAF Dimer Inhibitor Lifirafenib (BGB-283) & MEK Inhibitor Mirdametinib (PD-0325901)

Lusong Luo
 Senior Vice President,
 External Innovation
BeiGene

- How can inhibiting RAF dependent MEK reactivation suppress the proliferation of KRAS mutated cancer cells?
- Discuss methodologies of inhibiting tumor growths in KRAS mutant xenograft models
- Deconstruct the pharmacodynamic analysis of synergistic phospho-ERK blockade to confirm the antitumor activity in the KRAS mutant models
- Explore the decision to support a vertical inhibition strategy

9.40

6.40 Combination Therapies with SHP2 Inhibitors to Treat KRAS Mutant Cancers

**Peter
 Hammerman**
 Global Head of
 Oncology
Novartis

- Exploring the potential of SHP2i & G12Ci combination for KRAS G12C mutant cancers
- Benchmarking the effectivity of combining SHP2i & MAPKi to target KRAS mutant cancers
- Adopting CDK4/6i within combination for effective KRAS therapy combination approach for effective KRAS therapy

10.00

7.00 Real-World Data: Importance of Monitoring KRAS Mutations in Blood

Kerstin Pohl
 Manager of Medical
 Affairs
Biodesix

- Why is it important to monitor KRAS in blood with ddPCR?
- Analytical, clinical and real-world data for KRAS G12C mutations in NSCLC
- Bringing blood-based diagnostics from initial discovery to the clinic

10.20

7.20 Live Panel Q&A

Ask the speakers your burning Questions!



Steve Kelsey
 President R&D
**Revolution
 Medicines**



Lusong Luo
 Senior Vice President,
 External Innovation
BeiGene



**Peter
 Hammerman**
 Global Head of
 Oncology
Novartis



Kerstin Pohl
 Manager of Medical
 Affairs
Biodesix



11.00

8.00 Morning Break & Virtual Networking



**11.00
 8.00 Morning Break & Virtual Networking**

Early Discovery & Mechanism of Action

Translation & Clinical Development Considerations

Leveraging Small Molecules & Structural Mechanisms to Aid Effective RAS Targeting

The Promising Nature of RAS Combination Therapies – The Future of Oncology Treatment

11.30 8.30 Revealing New RAS Vulnerabilities Utilizing a Protein Interference Technology

- Discussing how PROTEINi technology has identified undiscovered targets which are synthetic lethal with RAS
- Through harnessing an effective toolkit, the SITESEEKER platform provides key pharmacophoric information about how to drug the undruggable



Grahame McKenzie
 Chief Scientific Officer
PhoreMost

11.30 8.30 Rigosertib as a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies

- Rigosertib targets RAS through mimetic interaction with effector proteins
- An update on the role of genetic and RAS pathway mutations in MDS RAS in the clinic



Steven Frutchman
 Chief Executive Officer
Onconava

11.50 8.50 Interrogating T50 Substitutions in KRAS Oligomerization & Function

- T50I gain of function mutations in RAS genes occur in mouse leukaemia's and patients with Noonan Syndrome
- Structural modelling indicates that T50 may lie in a RAS dimer/oligomer interface
- Functional analysis in human AML cell lines support a key role for T50 in KRAS activation



Pan-Yu Chen
 Postdoctoral Fellow
University of California

11.50 8.50 A Curative Therapy for Pancreatic Cancer

- Problems that need to be overcome with late stage pancreatic cancer
- A general strategy for bringing late stage pancreatic cancer patients to remission and preventing relapse
- Optimizing the utilization of oncogenic KRAS inhibitors in combination therapy



Nicholas Heimann
 Chief Executive Officer & Cancer Biologist
Nicholas Pharmaceuticals LLC

12.10 9.10 Synergistic Combinations with the Dual RAF/MEK Inhibitor VS-6766 to Overcome Resistance Mechanisms

- Unique mechanism of action of RAF/MEKi VS-6766 and relevance to overcoming resistance of RAS-driven tumors
- Synergistic combination with FAK inhibitor defactinib preclinically and clinically
- Synergistic combination with KRAS-G12C inhibitors



Jonathan Pachter
 Chief Scientific Officer
Verastem Oncology

12.10 9.10 Leveraging Synthetic Lethality of KRAS & PLK1 in Metastatic CRC Patients

- Second-line treatments for KRAS mutant mCRC patients is an unmet need and PLK1 is a promising therapeutic target for KRAS mutant CRC patients
- Onvansertib has significant anti-tumor activity in KRAS mutated CRC preclinical models
- Onvansertib in combination with FOLFIRI & bevacizumab in second-line KRAS mutant mCRC patients demonstrates safety and efficacy



Mark Erlander
 Chief Executive Officer
Cardiff Oncology

12.30 9.30 Mitochondrial Mediated Mechanisms of Resistance

- Understanding common mechanisms of resistance to targeted therapies
- Exploring mechanisms of reversing resistance to targeted therapies
- Highlight the role of the mitochondrial enzyme Sirt3 in RAS signalling



Jack Arbiser
 Thomas Lawley Professor of Dermatology
Emory School of Medicine

12.30 9.30 Leveraging Combination Approaches for Effective Use of G12C KRAS Inhibitors

- Understanding why pre-existing resistance to KRAS G12C inhibitors prevents their effectivity in clinical trials
- Discuss the different combination approaches which can ensure effective treatment of KRAS G12C mutant cancers and minimise resistance
- How studying the phenotype of effector immune cells can highlight the most optimal combinations of KRAS G12C inhibitors and immunotherapies



Miriam Molina-Arcas
 Senior Laboratory Research Scientist
Francis Crick Institute

12.50 9.50 Live Q&A Panel

- Ask Speakers Your Burning Questions

Panel Chair:



Shiva Malek
 Senior Director & Head of Discovery Oncology
Genentech



PhoreMost



University of California



Verastem Oncology



Emory School of Medicine

12.50 9.50 Live Q&A Panel

- Ask Speakers Your Burning Questions

Panel Chair:



Chiara Ambrogio
 Assistant Professor
University of Turin



Onconava



Nicholas Pharmaceuticals LLC



Cardiff Oncology



Francis Crick Institute

1.20

10.20 Networking Lunch & Roundtable Discussions

Join our informal interactive roundtable chat rooms to continue the RAS discussions!

2.00

11.00 Panel Discussion: Empowering Combination Strategies to Target RAS Mutant Cancers: The Future of Oncology Therapy

- What are the key factors to consider ensuring successful translation from discovery to clinic?
- The importance of moving beyond G12C – with the abundance of research surrounding G12C mutation, how and why should we be pushing for new avenues to explore?
- Technology, platforms & collaborations – what does the RAS community need in order to progress and produce effective, quality and safe RAS mutant cancer therapies?

Panel Chair:



Steven Frutchman
 President & Chief Executive Officer
Onconova Therapeutics

Panelists:



Jonathan Pachter
 Chief Scientific Officer
Verastem Oncology



Martin McMahon
 Presidential Chair Cancer Biology
University of Utah



Jan Smith
 Vice President Biology
Revolution Medicine



Peter Hammerman
 Global Head of Oncology
Novartis



2.45

11.45 Afternoon Break & Virtual Networking

Grab a coffee and a snack and join our virtual speed networking to make those long-lasting connections for your RAS targeted efforts!



2.45
11.45 Afternoon Break & Virtual Networking

Grab a coffee and a snack and join our virtual speed networking to make those long-lasting connections for your RAS targeted efforts!

Marie Evangelista
 Senior Scientist &
 Project Team Lead,
 Discovery Oncology
Genentech

3.15
12.15 Opportunities & Lessons for targeting KRAS

- Novel technologies to enable KRAS translational research and drug development
- Insights into tumor evolution following treatment with G12C covalent molecules

Udai Banerji
 Professor & Deputy
 Director of The Drug
 Development Unit
**The Institute of
 Cancer Research,
 London**

3.35
12.35 Clinical Combinations: Dual RAF-MEK Inhibitor & FAK for Treatment of KRAS Mutant Cancers With a Focus Low Grade Ovarian Cancer

- Discuss preclinical rationale for the combination of a dual RAF-MEK and FAK inhibitor
- Outline Phase I study including tolerability, pharmacokinetics and pharmacodynamics
- Consider the clinical efficacy in low grade serious ovarian cancer and comparison with other existing therapies

Scott Kopetz
 Distinguished
 Professor
**MD Anderson Cancer
 Centre**

3.55
12.55 Translating Rational Combinations Targeting RAS into the Clinic

- Discussing tumor specific observations from clinical trials
- Provide perspectives and rationale for novel combinations currently in or entering the clinic
- Review barriers to durable responses based on clinical and preclinical data

4.15
1.15 Live Q&A Panel

Ask Speakers Your Burning Questions



Marie Evangelista
 Senior Scientist &
 Project Team Lead,
 Discovery Oncology
Genentech



Udai Banerji
 Professor & Deputy Director of
 The Drug Development Unit
**The Institute of Cancer
 Research, London**



Scott Kopetz
 Distinguished Professor
MD Anderson Cancer Centre

4.45
1.45 Chair's Closing Remarks & End of the Digital 2nd RAS- Targeted Drug Development Summit

▶▶ The meeting content successfully captured the latest goings on in the field & brought together brought together all the key players in a setting that encouraged interaction ▶▶

Past Attendee, Revolution Medicines

DIGITAL PARTNERSHIP OPPORTUNITIES

Despite physical meeting restrictions, we are committed to serving you and our community members. To continue on our mission to serve the RAS community we have tailored bespoke partnership packages to help you stay competitive and nurture customer relationships through a digital world!



Benefit from Market Intelligence

Drugging the previously undruggable RAS targets opens tremendous opportunity to address the current unmet clinical need. Hear how and where pharmaceutical giants are looking for services and solutions to facilitate their R&D platforms and match your solutions accordingly



Virtually Meet & Network with Industry Pioneers

With a "room" full of drug developers looking to see how they can effectively translate their exciting early discovery efforts into safe and effective therapeutics, meet prospective clients during virtual speed networking breaks, bespoke 1-2-1 meetings and more informal networking receptions



Position Yourself as an Industry Expert

With the emergence of biotech companies focused on developing mutant-targeted RAS therapies, followed by interest shown from large pharma and investors, this meeting is a dedicated platform to put your independent expertise in front of the key decision-makers in the field



Raise Brand Awareness

Benefit from pre and post conference exposure to our drug discovery KOL community and increase market share through unique branding formats. Also, differentiate your discovery, preclinical and translational services from other solution providers




Generate Commercial Collaborations

Make sure your hottest prospects are in the room and part of the discussion by having a wish-list of your choice contacted in advance of the event

AUDIENCE COMPOSITION

SENIORITY OF ATTENDEES*




Director & Above: 47%

Senior Scientist & Team Leaders: 28%

Others: 25%

COMPANY BY TYPE



*Based on audience breakdown from RAS- Targeted Drug Discovery Boston 2019

“The RAS-Targeted Drug Discovery Summit was excellent. I learnt a lot on KRAS and also got to know what other people are working on in the community & it was very well organised”

Past Attendee, Glenmark Pharmaceuticals

REQUEST A DEMO



Jacob Roberts-Kendall

Partnership Director

E: sponsor@hansonwade.com

T: +1 617 455 4188

PROUD TO PARTNER WITH



Expertise Partner

We share your passion for science. Promega is committed to excellence in developing a broad suite of technologies for oncology. Learn how NanoBRET Target Engagement technology is being used to: target histone deacetylases, bromodomains, kinases, E3 ligases, and GPCRs; perform quantitative determinations of test compound affinity; monitor ligand occupancy in live cells, in real-time; and adapted for use in broad-spectrum profiling to evaluate the live-cell selectivity for test compounds. Let's collaborate.

www.promega.com



Expertise Partner

Biodesix® is an experienced partner in the field of blood-based molecular diagnostic testing. Our comprehensive diagnostic testing capabilities help our partners decipher the complexity of cancer by interpreting genomic and proteomic information from both tumor biology and the patient's immune response. Biodesix enables our partners throughout the discovery, development and commercialization of personalized diagnostics to support new therapies with companion diagnostic strategies.

www.biodesix.com



Exhibition Partner

Nanome is changing how we understand, design, and interact with science. Nanome's immersive virtual workspaces allow users to visualize, modify, and simulate chemical compounds, proteins, and nucleic acids to help improve the Drug Discovery process. Our virtual reality platform facilitates effective communication of structural data in drug discovery which has proved beneficial to several pharmaceutical and biotech companies across the globe. This is especially helpful for organizations that are interested in improving their cross-site collaboration.

www.nanome.com


Well organised, informative and good to meet fellow scientists

Past Attendee, The Beatson Institute

READY TO REGISTER?

3 EASY WAYS TO BOOK

 www.ras-drugdevelopment.com/register

 Tel: +1 617 455 4188

 Email: register@hansonwade.com

WHY JOIN THIS DIGITAL EVENT?



SAVE valuable time and resources by learning how leading companies in the space are advancing their anti-RAS therapies



GAIN first-hand insights on challenges and strategies on how to enhance and accelerate your RAS targeted discovery and development success



FORM lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively developing RAS targeted therapies

SECURE YOUR PLACE

Please select appropriate price when booking. Bookings are subject to approval

Industry Pricing	Standard Pricing
3 Day Pass - Conference & Workshop Day	\$3198
2 Day Pass - Conference Only	\$2299
1 Day Pass - Workshop Day Only	\$999
Academic Pricing	Standard Pricing
3 Day Pass - Conference & Workshop Day	\$2698
2 Day Pass - Conference Only	\$1999
1 Day Pass - Workshop Day Only	\$799

*Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge you will have the option to provide your VAT number and the charge will be automatically deducted at checkout. Visit the website for more details.

Team Discounts*

• **10% discount - 3 delegates**

• **15% discount - 5 delegates**

• **20% discount - 7+ delegates**

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate. For more information contact: register@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC2Y 0TH